Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Perforating artery territorial infarction (PAI) refers to a single ischaemic lesion <20 mm in
a single perforating arterial territory and branch atheromatous disease (BAD) is a important
etiological factor. BAD related infarction accounts for 10%-15% ischemic cerebral infarction
and is closely related to early neurological deterioration (END). Among patients with BAD,
dual antiplatelet (clopidogrel plus aspirin) did not significantly reduce the risk of
recurrent stroke. The primary purpose of this study is to assess the efficacy and safety of
tirofiban combined with aspirin versus placebo combined with aspirin in reducing the risk of
recurrence and progression of stroke at 90 days in patients with acute penetrating artery
territory infarction.
Phase:
Phase 4
Details
Lead Sponsor:
Beijing Tiantan Hospital
Collaborators:
Beijing Healthunion Cardio-Cerebrovascular Disease Prevention and Treatment Foundation GrandPharma (China) Co., Ltd.